ABSTRACT
BACKGROUND: Hand function impairment is the main disability among children with hemiplegic cerebral palsy. They start to perform most motor tasks exclusively with their unaffected upper limb, thereby causing a phenomenon described as learned nonuse. To minimize this phenomenon, constraint-induced movement therapy (CIMT) is emerging as a rehabilitation strategy for improving the functional use of the affected upper limb. OBJECTIVE: The aim of this study was to conduct a systematic review of the literature on the effects of CIMT among children with hemiparetic cerebral palsy. METHOD: This was a systematic review of the literature using randomized clinical trials to analyze the effects of CIMT on the functional performance of the affected upper limb among children with hemiparesis. RESULTS:Five studies fulfilled the inclusion criteria, and the methodological quality ranged from 2 to 6 (4.4±1.36), according to the PEDro scale. The studies included involved a total of 99 individuals who showed that CIMT had positive effects, compared with other rehabilitation strategies or no therapy. However, there was considerable variation between the studies regarding the measurement instruments used and the outcomes evaluated. CONCLUSION: Although the studies achieved positive results, it is difficult to draw any clear-cut conclusion regarding the effectiveness of CIMT because of the small number of studies and their methodological differences.
CONTEXTUALIZAÇÃO: A deficiência de função manual é a principal incapacidade em crianças com paralisia cerebral do tipo hemiplégica, as quais passam a realizar a maioria das tarefas motoras exclusivamente com o membro superior não acometido, determinando um fenômeno descrito como desuso aprendido. Para minimizar esse fenômeno, a terapia de movimento induzido por restrição (TMIR) emerge como estratégia de reabilitação para melhorar o uso funcional do membro superior acometido. OBJETIVO:O propósito desse estudo foi conduzir uma revisão sistemática da literatura para os efeitos da TMIR em crianças com hemiparesia devido à paralisia cerebral. MÉTODO: Revisão sistemática da literatura com ensaios clínicos aleatorizados analisando os efeitos da TMIR no desempenho funcional do membro superior acometido em crianças com hemiparesia. RESULTADOS:Cinco estudos preencheram os critérios de inclusão e a qualidade metodológica variou entre 2 e 6 (4.4±1.36) de acordo com a escala PEDro. Os estudos incluídos envolveram um total de 99 indivíduos e demonstraram efeitos positivos da TMIR em comparação a outras estratégias de reabilitação ou ausência de terapia. Entretanto, foram encontradas variações consideráveis nos estudos em relação aos instrumentos de medidas utilizados e os desfechos dos estudos. CONCLUSÃO: Embora os estudos tenham alcançado resultados positivos, a definição de uma conclusão sobre a efetividade da TMIR é dificultada em função do pequeno número de estudos e suas diferenças metodológicas.
ABSTRACT
Streptomyces microflavus strain No. 2445 produces many derivatives of fattiviracin antibiotics. The major product of these derivatives is fattiviracin FV-8, which consists of four glucose and two trihydroxy fatty acid residues. We found that this strain has the ability to convert several sugars in the culture medium to glucose, and the glucose added to the medium is directly incorporated into the FV-8 molecule. Two trihydroxy fatty acid residues in the FV-8 molecule are derived from acetic acid, and production of FV-8 is inhibited by the addition of cerulenin, which is an inhibitor of fatty acid biosynthesis.
Subject(s)
Antiviral Agents/metabolism , Glycolipids/biosynthesis , Streptomyces/metabolism , Antifungal Agents/pharmacology , Carbohydrate Metabolism , Carbohydrates/chemistry , Cell-Free System , Cerulenin/pharmacology , Culture Media , Glucose/metabolism , Glycolipids/chemistryABSTRACT
A novel antiviral agent, fattiviracin FV-8, purified from the culture broth of Streptomyces microflavus strain No. 2445, showed potent antiviral activities against human immunodeficiency virus type 1 (HIV-1), herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), and influenza A and B viruses. The action mechanism of fattiviracin FV-8 against HIV-1 was examined. As a result, the agent was thought to act on HIV-1 particles directly without lysis of the particles, and it affords the inhibition of viral entry into the host cells.
Subject(s)
Anti-HIV Agents/pharmacology , Antiviral Agents/pharmacology , Fatty Acids, Unsaturated/pharmacology , Glucose/pharmacology , Glycolipids/pharmacology , HIV-1/drug effects , Streptomyces , Animals , Cell Line , Chlorocebus aethiops , Dogs , Dose-Response Relationship, Drug , Herpesvirus 1, Human/drug effects , Herpesvirus 3, Human/drug effects , Humans , Influenza A virus/drug effects , Influenza B virus/drug effects , Vero CellsABSTRACT
Fattiviracin A1, showed potent antiviral activities against herpes simplex virus type 1 (HSV-1), varicella-zoster virus (VZV), influenza A virus and human immunodeficiency virus type 1 (HIV-1). It showed no cytotoxicity against Vero cells. Fattiviracin A1 exhibited no significant antibacterial or antifungal activities. Treatment of HSV-1 with fattiviracin A1 decreased its infectivity to Vero cells. The mechanism of its antiviral activity may be due to inactivation of the viral particles and inhibition of viral entry into host cells.
